Keywords
Plasmapheresis
Thrombotic Microangiopathy
How to Cite
Copyright © | All rights reserved.
The journal holds the exclusive copyright for the publication of this article under the terms of Brazilian law 9610/98.
Partial reproduction
The use of parts of the texts, figures and questionnaire of the article is free, being mandatory the citation of the authors and journal.
Total reproduction
It is expressly prohibited and must be authorized by the journal.
Abstract
Objective: Review about Thrombotic Thrombocytopenic Purpura (TTP). Bibliographic review: Thrombotic thrombocytopenic purpura (TTP) is a potential diagnosis in any patient with hemolytic anemia and thrombocytopenia and is a particular form of MAT (thrombotic microangiopathy), which encompasses several diseases characterized by microangiopathic hemolytic anemia, platelet aggregation and organ failure. Symptoms are generally non-specific and may include neurological changes, fever, renal failure, hemolytic anemia, thrombocytopenia. Final considerations: Once TTP of any etiology is diagnosed, the most effective treatment consists of plasma exchange, which consists of plasmapheresis and infusion of fresh frozen plasma (PFC). Even in critically ill patients, plasmaphere still has dramatic effects. Platelet transfusion is normally contraindicated in TTP, due to the risk of increasing the formation of microthrombi, worsening neurological and renal function. In case of relapse, recent evidence suggests a possible role for rituximab (anti-CD20 antibody), that is: a drug that specifically neutralizes antibody-producing B lymphocytes.
References
CASTELLANO MEM, et al. Recomendaciones para el abordaje clínico de pacientes con púrpura trombocitopénica trombótica. Med Clin (Barc), 2022; 158:630.
CHANDER DP, et al. Caplacizumab Therapy without Plasma Exchange for Acquired Thrombotic Thrombocytopenic Purpura. N Engl J Med, 2019; 381:92.
CUKER A, et al. Redefining outcomes in immune TTP: an international working group consensus report. Blood, 2021; 137:1855.
GALSTYAN GM,. et al. [Treatment of thrombotic thrombocytopenic purpura]. Ter Arkh, 2021; 93(7):826-829. Russian.
HANSEN DL, et al. Thrombotic thrombocytopenic purpura. Ugeskr Laeger, 2021; 183:3210230.
LONG B, et al. Evaluation and Management of Thrombotic Thrombocytopenic Purpura in the Emergency Department. J Emerg Med, 2021; 61(6):674-682.
KESSLER CS, et al. Thrombotic thrombocytopenic purpura: a hematological emergency. J Emerg Med, 2012.
LIM W, et al. The role of rituximab in the management of patients with acquired thrombotic thrombocytopenic purpura. Blood, 2015; 125(10):1526-31.
MARTIN SD, et al. Indicators Differentiating Thrombotic Thrombocytopenic Purpura From Other Thrombotic Microangiopathies in a Canadian Apheresis Referral Center. Am J Clin Pathol, 2021; 156(6):1103-1112.
NOBREGA T, et al. Registro brasileiro de púrpura trombocitopênica trombótica: análise demográfica e perfil clínico de uma coorte ambispectiva. Hematology, Transfusion and Cell Therapy, 2023; Volume 45, Supplement 4, P. S485.
OLIVEIRA DS, et al. Plasmic score applicability for the diagnosis of thrombotic microangiopathy associated with ADAMTS13-acquired deficiency in a developing country. Hematology Transfusion and Cell Therapy, 2019; 41(2), 119–124.
PASCUAL-IZQUIERDO C, et al. Immune thrombotic thrombocytopenic purpura: clinical suspicion and basic management in emergency departments - an expert review and consensus statement from the Spanish societies of hematology and hemotherapy (SEHH) and emergency medicine (SEMES). Emergencias, 2023; 35(1):44-52.
POLITO MG, et al. Microangiopatias trombóticas: púrpura trombocitopênica trombótica e síndrome hemolítico-urêmica. J Bras Nefrol, 2010; 32(3):303-315.
PREVEL R, et al. Immune thrombotic thrombocytopenic purpura in older patients: prognosis and long-term survival. Blood, 2019; 134:2209.
ROMERO S, et al. Practice guidelines for the emergency treatment of thrombotic microangiopathy. Med Clin, 2018; 151:123.e1–9.
SAWLER D, et al. Time from suspected thrombotic thrombocitopenic purpura to initiation of plasma Exchange and impacto n survival: A 10-year provincial retrospective cohort study. Thrombosis Research, 2020; 193:53-59.
SCHOFIELD J, et al. Drug-induced thrombotic thrombocytopenic purpura: A systematic review and review of European and North American pharmacovigilance data. Br J Haematol, 2023; 201:766.
SCULLY M. A 'needle in a haystack': Drug-induced thrombotic thrombocytopenic purpura-Association or causality?. Br J Haematol, 2023; 201:599.
SCULLY M, et al. Caplacizumab Treatment for Acquired Thrombotic Thrombocytopenic Purpura. engl j med, 2019; 380;4.
SINIARD RC, et al. Challenges in the diagnosis of thrombotic thrombocytopenic purpura. Expert Rev Hematol, 2023; 16(11):861-869.
SUBHAN M e SCULLY M. Advances in the management of TTP. Blood Rev, 2022; 55:100945.
TELLEZ-HINOJOSA C, et al. Thrombotic thrombocytopenic purpura. Medicina Universitaria, 2015; 234-239.
TONACO LC, et al. Púrpura trombocitopênica trombótica: o papel do fator von Willebrand e da ADAMTS13. Rev. Bras. Hematol. Hemoter, 2010; 32(2):155-161.